221 related articles for article (PubMed ID: 26552971)
1. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
Armstrong ES; Farrell DJ; Palchak M; Steenbergen JN
Antimicrob Agents Chemother; 2016 Jan; 60(1):666-8. PubMed ID: 26552971
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
3. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
4. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
5. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Scott LJ
Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Eckmann C; Solomkin J
Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
[TBL] [Abstract][Full Text] [Related]
7. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.
Snydman DR; McDermott LA; Jacobus NV
Antimicrob Agents Chemother; 2014; 58(2):1218-23. PubMed ID: 24277025
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
Miller B; Popejoy MW; Hershberger E; Steenbergen JN; Alverdy J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4387-90. PubMed ID: 27139477
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
Mikamo H; Monden K; Miyasaka Y; Horiuchi T; Fujimoto G; Fukuhara T; Yoshinari T; Rhee EG; Shizuya T
J Infect Chemother; 2019 Feb; 25(2):111-116. PubMed ID: 30528561
[TBL] [Abstract][Full Text] [Related]
11. The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.
Goldstein EJ; Citron DM; Tyrrell KL; Leoncio ES; Merriam CV
Anaerobe; 2017 Feb; 43():1-3. PubMed ID: 27713022
[TBL] [Abstract][Full Text] [Related]
12. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Sucher AJ; Chahine EB; Cogan P; Fete M
Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
[TBL] [Abstract][Full Text] [Related]
16. Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections.
Claros M; Citron DM; Goldstein EJ; Merriam CV; Tyrrell KL
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):546-8. PubMed ID: 23727512
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital.
Tan TY; Ng LS; Kwang LL; Rao S; Eng LC
Anaerobe; 2017 Feb; 43():69-74. PubMed ID: 27890724
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial resistance in the Bacteroides fragilis group in faecal microbiota from healthy Danish children.
Sydenham TV; Jensen BH; Petersen AM; Krogfelt KA; Justesen US
Int J Antimicrob Agents; 2017 May; 49(5):573-578. PubMed ID: 28366659
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
Yim J; Lee Y; Kim M; Seo YH; Kim WH; Yong D; Jeong SH; Lee K; Chong Y
Ann Lab Med; 2015 Jan; 35(1):94-8. PubMed ID: 25553287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
